Paragon 28, Inc. has launched the Phantom® Fibula Nail System, offering a less invasive approach to fibular fracture treatment in ankle injuries. The system, designed to provide an alternative to traditional plate and screw fixation, purportedly addresses some of the complications associated with external fixation methods.
GE HealthCare has introduced the Venue Sprint, a new tablet-based ultrasound device, alongside enhancements to its existing Venue family of point-of-care ultrasound (POCUS) systems. The launch aims to address the growing demand for portable, high-quality imaging solutions in various clinical settings.
GE HealthCare has introduced the Versana Premier, a new multi-purpose ultrasound system designed to meet the diverse needs of healthcare professionals across various clinical specialties. The system, which forms part of the Versana ultrasound family, incorporates artificial intelligence (AI) and automated productivity tools to streamline workflow and improve clinical efficiency.
Catalyst OrthoScience, a medical technology company specialising in shoulder arthroplasty, has announced FDA 510(k) clearance for its Catalyst Fracture Shoulder System. The system, designed for reverse shoulder arthroplasty in cases of proximal humeral fractures (PHFs), aims to tackle the complexities associated with tuberosity fixation and healing.
bioAffinity Technologies’ Vice President of Diagnostics, Dr Jennifer Rebeles, has contributed to a new set of guidelines for flow cytometry testing on rare matrix samples. The peer-reviewed paper, published in Cytometry Part B: Clinical Cytometry, addresses the challenges and considerations in validating assays with unique sample types.
New research reveals that men and women rely on distinct biological mechanisms for pain relief, potentially explaining sex differences in chronic pain prevalence and opioid treatment efficacy.
AtriCure has announced regulatory approval for the sale of its EnCompass® Clamp in CE-marked countries within the European Union. This development follows the device’s FDA 510(K) clearance and subsequent launch in the United States in 2022.
A new study projects significant reductions in postoperative complications and substantial cost savings through the implementation of a system-wide preoperative nutrition programme.
Researchers have developed a new treatment approach for type 2 diabetes that could potentially eliminate the need for insulin therapy in a majority of patients, according to findings presented at UEG Week 2024 in Vienna.
New research challenges long-held beliefs about the causes of gout, highlighting the significant impact of genetics on the chronic inflammatory condition.
Beukenlaan 137
5616 VD Eindhoven
The Netherlands
+31 85064 55 82
info@interhospi.com
PanGlobal Media IS not responsible for any error or omission that might occur in the electronic display of product or company data.
